From 4 in 10,000 to 1 in 100: The autism explosion that isn’t
Matt Donnelly examines the dramatic rise in autism diagnoses and explains why better recognition is behind the increased prevalence.
Matt Donnelly examines the dramatic rise in autism diagnoses and explains why better recognition is behind the increased prevalence.
A recent study, published on Nature Neuroscience, lays groundwork for potential development of first neurobiologically-based therapy for patients with autism spectrum disorders (ASD). This research from the O’Donnell Brain Institute in the U.S. explored a specific area within the right cerebellum, called CrusI. Whilst cerebellar abnormalities in ASD patients were known for some time, the…